Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Fineline Cube Jan 30, 2026
Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026
Company Medical Device

Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance

Fineline Cube Apr 21, 2025

Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...

Company Drug

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101

Fineline Cube Apr 21, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...

Company Drug

Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria

Fineline Cube Apr 21, 2025

France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...

Company Drug

Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China

Fineline Cube Apr 21, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

Fineline Cube Apr 21, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Drug

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine

Fineline Cube Apr 21, 2025

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...

Company

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs

Fineline Cube Apr 21, 2025

hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...

Company Deals

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development

Fineline Cube Apr 21, 2025

China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...

Company Drug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

Fineline Cube Apr 21, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received...

Company Drug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 21, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...

Company Medical Device

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System

Fineline Cube Apr 21, 2025

US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study

Fineline Cube Apr 21, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has received clearance from the National Medical...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658

Fineline Cube Apr 21, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...

Company Drug

AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment

Fineline Cube Apr 21, 2025

China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s (AZ, NASDAQ: AZN) Truqap (capivasertib) for...

Company Drug

Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone

Fineline Cube Apr 21, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...

Company Drug

Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment

Fineline Cube Apr 18, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Fineline Cube Apr 18, 2025

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company Deals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Fineline Cube Apr 18, 2025

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...

Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Fineline Cube Apr 18, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has completed a 70,000-square-foot expansion at its Myerstown,...

Company Drug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China

Fineline Cube Apr 18, 2025

The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...

Posts pagination

1 … 125 126 127 … 616

Recent updates

  • Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
  • Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials
  • Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
  • CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio
  • Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.